Evidence map›Paper›PMID 36518054›Full record

ArticleJournal of Zhejiang University. Science. B2022

Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-α induced by urotensin II.

Jun Li, Limin Luo, Yonggang Zhang, Xiao Dong, Shuyi Dang, Xiaogang Guo, Wenhui Ding

Open access · greenAbstract read
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jun LiDepartment of Cardiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Limin LuoDepartment of Dermatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Yonggang ZhangDepartment of Cardiovascular Diseases, the Second Affiliated Hospital, Shantou University Medical College, Shantou 515041, China.
Xiao DongDivision of Cardiology, Department of Internal Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
Shuyi DangDivision of Cardiology, Department of Internal Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
Xiaogang GuoDepartment of Cardiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Wenhui DingDivision of Cardiology, Department of Internal Medicine, Peking University First Hospital, Beijing 100034, China. dwh_rd@126.com.
Hubei University of Medicine · CNFirst Affiliated Hospital Zhejiang University · CNPeking University · CNShantou University · CN

Funding

the Educational Commission of Hubei Province B2017112 and B20181130the Natural Science Foundation of Hubei Province 2018CFB747 and 2018CFB537the the National Natural Science Foundation of China 82003372
6 · The paper itself

Abstract

objectivesIn this study, we explored how adiponectin mediated urotensin II (UII)‍-induced tumor necrosis factor-‍α (TNF-‍α) and α‍-smooth muscle actin (α‍-SMA) expression and ensuing intracellular signaling pathways in adventitial fibroblasts (AFs).

methodsGrowth-arrested AFs and rat tunica adventitia of vessels were incubated with UII and inhibitors of signal transduction pathways for 1‍‒‍24 h. The cells were then harvested for TNF-α receptor (TNF-‍α-R) messenger RNA (mRNA) and TNF-‍α protein expression determination by reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. Adiponectin and adiponectin receptor (adipoR) expression was measured by RT-PCR, quantitative real-time PCR (qPCR), immunohistochemical analysis, and cell counting kit-8 (CCK-8) cell proliferation experiments. We then quantified TNF-α and α-SMA mRNA and protein expression levels by qPCR and immunofluorescence (IF) staining. RNA interference (RNAi) was used to explore the function of the adipoR genes. To investigate the signaling pathway, we applied western blotting (WB) to examine phosphorylation of adenosine 5'-monophosphate (AMP)‍-activated protein kinase (AMPK). In vivo, an adiponectin (

resultsIn both cells and tissues, UII promoted TNF-α protein and TNF-α-R secretion in a dose- and time-dependent manner via Rho/protein kinase C (PKC) pathway. We detected marked expression of adipoR1, T-cadherin, and calreticulin as well as a moderate presence of adipoR2 in AFs, while no adiponectin was observed. Globular adiponectin (gAd) fostered the growth of AFs, and acted in concert with UII to induce α-SMA and TNF-α through the adipoR1/T-cadherin/calreticulin/AMPK pathway. In AFs, gAd and UII synergistically induced AMPK phosphorylation. In the adventitial inflammation model,

conclusionsFrom the results of our study, we can speculate that UII induces TNF‍-‍α protein and TNF-‍α‍-R secretion in AFs and rat tunica adventitia of vessels via the Rho and PKC signal transduction pathways. Thus, it is plausible that adiponectin is a major player in adventitial progression and could serve as a novel therapeutic target for cardiovascular disease administration.

Indexed as

AdventitiaTumor Necrosis Factor-alphaAMP-Activated Protein KinasesAnimalsCalreticulinCells, CulturedInflammationMiceRatsRNA, MessengerUrotensinsVascular RemodelingAMP-Activated Protein KinasesCalreticulinRNA, MessengerTumor Necrosis Factor-alphaurotensin IIUrotensinsAdiponectinAdiponectin-knockout (APN-KO)Adventitial fibroblastRNA interference (RNAi)Signal transductionUrotensin II

Identifiers

PMID36518054
PMCPMC9758717
OpenAlexW4312065827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.